The link between the intestinal microbiota and gut inflammation in IBD in humans and NE in poultry supports selective manipulation of the microbiota composition as a therapeutic strategy. Butyrate producing bacteria have significant anti-inflammatory potential due to production of butyrate and other extracellular compounds. The aim is to investigate anti-inflammatory properties of newly isolated butyrate producing bacteria to use for treatment of IBD and NE.